Apolipoproteins A and B and PCSK9: Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease and in End-Stage Renal Disease
Joint Authors
Foia, Lili
Toma, Vasilica
Vlad, Cristiana
Rezus, Ciprian
Popescu, Roxana
Ivanov, Iuliu
Luca, Mihaela Catalina
Delianu, Carmen
Statescu, Cristian
Florea, Laura
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-17, 17 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-12-14
Country of Publication
Egypt
No. of Pages
17
Main Subjects
Abstract EN
Purpose.
Nontraditional cardiovascular risk factors as apolipoprotein A (ApoA), apolipoprotein B (ApoB), and the proprotein convertase subtilisin/kexin type 9 (PCSK9) increase the prevalence of cardiovascular mortality in chronic kidney disease (CKD) or in end-stage renal disease (ESRD) through quantitative alterations.
This review is aimed at establishing the biomarker (ApoA, ApoB, and PCSK9) level variations in uremic patients, to identify the studies showing the association between these biomarkers and the development of cardiovascular events and to depict the therapeutic options to reduce cardiovascular risk in CKD and ESRD patients.
Methods.
We searched the electronic database of PubMed, Scopus, EBSCO, and Cochrane CENTRAL for studies evaluating apolipoproteins and PCSK9 in CKD and ESRD.
Randomized controlled trials, observational studies (including case-control, prospective or retrospective cohort), and reviews/meta-analysis were included if reference was made to those keys and cardiovascular outcomes in CKD/ESRD.
Results.
18 studies met inclusion criteria.
Serum ApoA-I has been significantly associated with the development of new cardiovascular event and with cardiovascular mortality in ESRD patients.
ApoA-IV level was independently associated with maximum carotid intima-media thickness (cIMT) and was a predictor for sudden cardiac death.
The ApoB/ApoA-I ratio represents a strong predictor for coronary artery calcifications, cardiovascular mortality, and myocardial infarction in CKD/ESRD.
Plasma levels of PCSK9 were not associated with cardiovascular events in CKD patients.
Conclusions.
Although the “dyslipidemic status” in CKD/ESRD is not clearly depicted, due to different research findings, ApoA-I, ApoA-IV, and ApoB/ApoA-I ratio could be predictors of cardiovascular risk.
Serum PCSK9 levels were not associated with the cardiovascular events in patients with CKD/ESRD.
Probably in the future, the treatment of dyslipidemia in CKD/ESRD will be aimed at discovering new effective therapies on the action of these biomarkers.
American Psychological Association (APA)
Vlad, Cristiana& Foia, Lili& Popescu, Roxana& Ivanov, Iuliu& Luca, Mihaela Catalina& Delianu, Carmen…[et al.]. 2019. Apolipoproteins A and B and PCSK9: Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease and in End-Stage Renal Disease. Journal of Diabetes Research،Vol. 2019, no. 2019, pp.1-17.
https://search.emarefa.net/detail/BIM-1173152
Modern Language Association (MLA)
Vlad, Cristiana…[et al.]. Apolipoproteins A and B and PCSK9: Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease and in End-Stage Renal Disease. Journal of Diabetes Research No. 2019 (2019), pp.1-17.
https://search.emarefa.net/detail/BIM-1173152
American Medical Association (AMA)
Vlad, Cristiana& Foia, Lili& Popescu, Roxana& Ivanov, Iuliu& Luca, Mihaela Catalina& Delianu, Carmen…[et al.]. Apolipoproteins A and B and PCSK9: Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease and in End-Stage Renal Disease. Journal of Diabetes Research. 2019. Vol. 2019, no. 2019, pp.1-17.
https://search.emarefa.net/detail/BIM-1173152
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1173152